Business Context and Reporting Period
Company: Oramed Pharmaceuticals Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 2, 2025
Subject: Entry into a Material Definitive Agreement regarding the deferral of debt obligations and receipt of equity/royalty rights from Scilex Holding Company ("Scilex").
Key Financial Metrics and Transaction Details
This filing does not report standard periodic financial metrics (revenue, profit, cash flow) but details a specific debt restructuring transaction:
- Debt Instrument: Tranche B Senior Secured Convertible Note with an aggregate principal amount of $50,000,000.
- Original Obligation: First Amortization Payment of $6,250,000 per fiscal quarter, originally due January 2, 2025.
- Immediate Cash Consideration: Scilex agreed to pay an aggregate of $1.11 million to Tranche B Noteholders regarding a portion of the First Amortization Payment and related make-whole interest.
- Equity Consideration: SCLX Stock Acquisition JV agreed to deliver 5,000,000 shares of Oramed common stock to the Noteholders (2,500,000 shares to Oramed).
- Royalty Rights: Noteholders to receive a 4% royalty on worldwide Net Sales of Gloperba and Elyxyb (excluding Elyxyb sales in Canada) for 10 years.
Material Changes and Deferrals
The filing outlines significant changes to the repayment schedule of the Tranche B Notes:
- Short-Term Deferral: The First Amortization Payment due January 2, 2025, has been deferred to January 31, 2025.
- Long-Term Deferral: Subject to the execution of a Term Sheet and delivery of shares, the obligation to make the First Amortization Payment is further deferred until October 8, 2026.
- Related Debt Extension: A separate Senior Secured Promissory Note (approx. $25 million final installment) currently due March 21, 2025, is contingent on an extension to December 31, 2025. This extension is a closing condition for the Term Sheet and is not yet finalized.
Outlook, Risks, and Contingencies
Management Commentary and Conditions:
- The long-term deferral and royalty rights are contingent upon Scilex securing an extension of its obligations under the Senior Secured Promissory Note issued on September 21, 2023.
- Oramed has no obligation to provide this extension; it is dependent on the achievement of definitive documents acceptable to the Company in its discretion.
- Noteholders have the right (but not obligation) to fund up to 50% of the cash purchase price for an Ex-US Product Right, entitling them to proportional revenues.
- Failure to secure the extension of the Senior Secured Promissory Note may prevent the long-term deferral of the Tranche B Notes.
- The transaction involves complex conditions regarding the delivery of shares and the execution of the Term Sheet.
Investor Verification Checklist
- Verify the execution of the definitive agreement extending the Senior Secured Promissory Note maturity to December 31, 2025.
- Confirm the delivery of the 5,000,000 Oramed common shares to the Tranche B Noteholders.
- Monitor the receipt of the $1.11 million payment by the Noteholders.
- Review the final terms of the Term Sheet regarding the 4% royalty on Gloperba and Elyxyb sales.
- Assess the impact of the deferred amortization payments on Scilex's liquidity and Oramed's secured creditor status.